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Abstract: Ischaemia in the heart is accompanied by the accumulation of long-chain acylcarnitines (LCACs) which is one of the
multiple factors that contribute to the ischaemia–reperfusion damage development. Long-term pre-treatment that decreases car-
nitine and LCAC contents also reduces ischaemia–reperfusion (IR) damage; however, the duration of the post-treatment effects is
not known. The aim of the study was to assess the post-treatment effects of the carnitine transport (OCTN2) inhibitor, methyl-
GBB, on LCAC content and the duration of its cardioprotective effect. Male Wistar rats received methyl-GBB (5 mg/kg for
28 days), and the anti-infarction effects on Langendorff-perfused hearts and the acylcarnitine profile in cardiac tissues were mea-
sured up to 28 days following the end of the treatment. Methyl-GBB pre-treatment for 28 days decreased LCAC heart tissue
content by 87%, and the infarct size was decreased by 57%. Fourteen days post-treatment, the LCAC content was still decreased
by 69%, and the infarct size was decreased by 32% compared to Control. A significant Pearson correlation (r = 0.48, p = 0.026)
was found between infarct size and LCAC tissue content in the methyl-GBB-treated rat hearts. The addition of 2 mM carnitine
to isolated heart perfusate significantly diminished the methyl-GBB-induced decrease in LCACs and infarct size. In conclusion,
the anti-infarction effect of methyl-GBB continues for at least 2 weeks post-treatment. No less than a 70% decrease in LCAC
content is required to protect ischaemic heart tissues, and the decrease in LCAC levels defines the duration of the post-treatment
cardioprotective effect of the OCTN2 inhibitor, methyl-GBB.
Ischaemic conditions in the heart are accompanied by
impaired mitochondrial oxidative metabolism [1] and the
accumulation of non-metabolized fatty acid (FA) metabolism
intermediates [2,3]. In particular, the accumulation of long-
chain acylcarnitines (LCACs; esters of FAs and carnitine) fur-
ther inhibits oxidative phosphorylation [4], impairs cell insulin
signalling [5,6], modulates cell membrane ion channels,
increases membrane permeability and activates cell stress
pathways [7]. LCAC content can be effectively decreased
using compounds that decrease the availability of carnitine,
which is required for LCAC synthesis by CPT-1 [8,9], and
inhibitors of the carnitine transporter, OCTN2, are far more
effective in decreasing carnitine content than are inhibitors of
c-butyrobetaine dioxygenase [10], which is the final enzyme
in the carnitine biosynthesis pathway. Methyl-GBB (4-[ethyl
(dimethyl)ammonio]butanoate) is the most known potent com-
pound to decrease the heart and muscle tissue content of car-
nitine and LCACs; this compound possesses cardioprotective
properties without changing heart function [8,9,11] and
improves insulin sensitivity in db/db mice with type 2 dia-
betes [12]. By decreasing carnitine-dependent long-chain fatty
acid (LCFA) oxidation and LCAC content, methyl-GBB
stimulates basal and insulin-stimulated glucose oxidation in
the normoxic heart [8].
Similar to methyl-GBB in its mechanism of action, particu-
larly regarding the inhibition of OCTN2, is the clinically used
cardioprotective compound meldonium [13], which recently
attracted increased attention from the World Anti-Doping
Agency due to numerous findings of meldonium in athletes’
blood and urine [14–16]. One finding of particular interest is
that meldonium is found in blood samples in significant con-
centrations even 16 days after the administration of a single
dose [16]. The authors assumed that meldonium is taken up
by erythrocytes, whereas our findings have well documented
that meldonium and methyl-GBB are both taken up by all
tested tissues, creating significant depots of either of these
substances [8,9,17] that will slowly release the compounds
after the treatment has ended. Indeed, even 4 weeks after the
end of treatment, plasma concentrations of meldonium in
healthy volunteers are approximately 1 lM (approximately 20
times lower than the concentrations found during the treat-
ment) [18]. It is known that meldonium competes with car-
nitine for transport via OCTN2 [19,20], and meat
consumption (a natural source of dietary carnitine) is corre-
lated with the carnitine-decreasing effect of meldonium [21],
whereas co-treatment with carnitine can completely remove
the cardioprotective effect of meldonium [22]. Methyl-GBB is
a significantly more potent inhibitor of OCTN2-mediated
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carnitine transport than meldonium and is well transported into
tissues (OCTN2 IC50 is 3 lM for methyl-GBB [8] versus
21 lM for meldonium [20]), and it can be assumed that
methyl-GBB might also be retained in significant amounts in
tissues post-treatment, thus providing prolonged biochemical
consequences and anti-infarction effect after the end of treat-
ment.
To determine the duration of the cardioprotective effect of
methyl-GBB after the end of the compound administration, we
treated rats for 28 days and assessed the myocardial infarct
size immediately after the end of treatment until no cardiopro-
tection was observed. In parallel, tissue concentrations of
methyl-GBB, carnitine, its precursor GBB and the FA metabo-
lites acylcarnitines were measured to better understand the
pharmacokinetics of the strong OCTN2 inhibitor and to assess
the role of various acylcarnitine, particularly LCAC, levels on
the outcome of ischaemia–reperfusion damage. Previously, it
has been shown that the acute addition of carnitine to the per-
fusion solution can worsen the outcome after global ischaemia
by impairing glucose metabolism [23]. Because LCAC can
effectively impair glucose metabolism [24], we studied the
effects of methyl-GBB on changes in the LCAC content and
cardioprotective efficacy after acute carnitine addition to the
isolated heart perfusion solution.
Materials and Methods
Materials. Methyl-GBB was obtained from JSC Grindeks (Riga,
Latvia). Krebs–Henseleit buffer components potassium
dihydrogenphosphate, sodium chloride, calcium chloride dihydrate,
potassium chloride, sodium bicarbonate and magnesium chloride
hexahydrate were purchased from Acros Organics (Geel, Belgium).
Ethylenediamine-tetraacetate sodium salt (EDTA) and triphenyl-
tetrazolium chloride were purchased from Sigma-Aldrich (Schnelldorf,
Germany). Sodium pentobarbital (Dorminal) solution was purchased
from Alfasan (Woerden, Holland). Heparin sodium was purchased
from Panpharma (Fougeres, France).
Animals and treatment. Male Wistar rats (n = 86) weighing 200–
250 g (7–8 weeks old) were obtained from the Laboratory of
Experimental Animals, Riga Stradins University (Riga, Latvia) and
housed for 2 weeks prior to treatment under standard conditions (21–
23°C, 12-hr light/dark cycle, relative humidity 45–65%) with unlimited
access to food [R70 diet from Lantm€annen, (Stockholm, Sweden)] and
water. The experimental procedures were performed in accordance with
the guidelines of the European Community and local laws and policies,
and all of the procedures were approved by the Food and Veterinary
Service, Riga, Latvia. All experiments were performed in a blinded
manner. Studies involving animals are reported in accordance with the
ARRIVE guidelines [25,26]. All experimental groups and animals per
group are shown in Table S1. To determine post-treatment effects,
animals were randomly separated into two experimental groups and
given daily oral doses of water (Control group, n = 18) or 5 mg/kg
methyl-GBB (n = 24) for 28 days. Methyl-GBB treated rats and age-
matched Control group rats were used for myocardial infarction study
right after the 28-day treatment and 14 and 28 days post-treatment.
Additional infarction experiment [Control group n = 8, methyl-GBB
treated n = 14 (n = 7 methyl-GBB and n = 7 methyl-GBB+2 mM
carnitine)] was performed when 2 mM carnitine was added to the
perfusion solution of methyl-GBB-treated rat isolated hearts. To
determine changes in acylcarnitine profile when 2 mM carnitine is
added to perfusion solution of methyl-GBB treated rat hearts, another
experiment was performed where hearts were sectioned immediately
after ischaemia and acylcarnitines measured in risk area [Control group,
methyl-GBB treated group and methyl-GBB treated + 2 mM carnitine
group (n = 6 per each group)]. Four rats were used to determine methyl-
GBB plasma half-life after per oral administration of methyl-GBB at a
single dose of 5 mg/kg. Non-fasting blood samples were collected from
tail veins; samples were centrifuged, and the plasma was stored at
80°C for analysis at a later time.
Isolated rat heart infarction study. To determine the duration of anti-
infarction effect of methyl-GBB, the first experiment was performed
using hearts from methyl-GBB-treated animals immediately after 28-
day treatment and 14 and 28 days post-treatment with the compound.
For each time-point, data from methyl-GBB-treated rats were
compared with data from age-matched control animals. The infarction
was performed according to the Langendorff technique as described
previously [22], with some modifications. For the infarction studies,
the hearts were perfused with Krebs–Henseleit (KH) buffer solution at
a constant perfusion pressure of 60 mmHg. The isolated rat hearts
were adapted for 20 min., and the left anterior descending coronary
artery (LAD) was subsequently occluded for 30 min. followed by
120 min. of reperfusion. Infarct size was determined as described
previously [27]. Briefly, at the end of reperfusion, LAD was re-
occluded and heart was perfused with 0.1% methylene blue dissolved
in KH buffer solution. Afterwards, the ventricles of the heart were
transversely cut into 2-mm-thick slices, treated with triphenyl-
tetrazolium chloride (TTC) and photographed. Unsliced part of the
heart was not treated with TTC, but immediately frozen until further
analysis of acylcarnitines, carnitine, GBB and methyl-GBB.
Computerized planemetric analysis of stained left ventricle slice
photographs was performed using Image-Pro Plus v6.3 software
(Media Cybernetics Inc., Rockville, MD, USA) to determine the area
at risk (AR) and the area of necrosis (AN), and each area was
expressed as a percentage of the left ventricle area. The obtained
values were then used to calculate the infarct size (IS) as a percentage
of the risk area, according to the formula IS = AN/AR 9 100%. Two
additional infarction experiments were performed to determine effects
of acute carnitine addition to the perfusion solution on infarct size and
LCAC content in methyl-GBB-treated rat hearts. For experiments with
2 mM carnitine in the perfusion solution, adaptation time was
increased to 30 min. to allow carnitine to enter tissues. During
ischaemia and reperfusion, hearts were perfused with normal KH
perfusion solution. In one experiment, infarct size was determined as
described above, while in the second experiment the contents of
acylcarnitines were measured in tissues from risk area of hearts
immediately after ischaemia without reperfusion.
Measurement of carnitine, GBB, methyl-GBB and acylcarnitines by
UPLC/MS/MS. Determination of carnitine, GBB, methyl-GBB in
heart tissues and plasma samples was performed by ultraperformance
liquid chromatography–tandem mass spectrometry (UPLC/MS/MS)
using the positive ion electrospray mode [8]. Determination of the
acylcarnitines in the heart tissue and plasma samples was performed
by UPLC MS/MS method [24] and samples prepared as previously
described [8].
Statistical methods. Data are presented as the mean  S.E.M.
Statistically significant differences in the mean values were evaluated
using Student’s t-test and one-way ANOVA followed by Tukey’s test.
Student’s t-test was used to compare results of methyl-GBB treated
group to respective Control group at the same time-point. One-way
ANOVA followed by Tukey’s test was used to compare methyl-GBB
tissue concentration changes at different post-treatment time-points.
One-way ANOVA followed by Tukey’s test was also used to compare
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anti-infarction effect of methyl-GBB in the presence or absence of
carnitine in the perfusion solution. Correlation was tested using the
Pearson method. The differences were considered significant when
p < 0.05. The data were analysed using GraphPad Prism statistical
software (Graph Pad Inc., La Jolla, CA, USA).
Results
Isolated rat heart infarction.
A heart infarction study was performed after 4 weeks of treat-
ment with methyl-GBB at a dose of 5 mg/kg and also at 14
and 28 days after the last administration of the drug to deter-
mine the time at which the cardioprotective effect ends. Treat-
ment with methyl-GBB significantly decreased (by 57%)
myocardial infarct size after 28 days of treatment compared to
the Control group. Significantly decreased myocardial infarct
size (by 32%) was also observed 14 days after the end of
methyl-GBB administration; however, 28 days after the end of
the treatment, no significant cardioprotection was observed
(fig. 1A). A significant Pearson correlation was observed
between infarct size and tissue content sum of LCAC
(r = 0.48, p = 0.026), sum of medium-chain acylcarnitines
(MCAC) (r = 0.47, p = 0.029), sum of short-chain acylcarniti-
nes (SCAC) (r = 0.63, p = 0.0021) and carnitine (r = 0.66,
p = 0.001). Contents of individual acylcarnitines C2, C14,
C16, C18 and C18:2 correlated with the infarct size, while no
significant correlation was for tissue contents of individual
acylcarnitines C4, C6, C8, C10 and C12 (figs 2A and 2B,
Table S2).
An additional experiment in which 2 mM carnitine was
added to the perfusion buffer was performed to test the role of
free carnitine and LCAC decrease on the cardioprotective
effect of methyl-GBB. In this experiment, methyl-GBB admin-
istration resulted in significantly decreased infarct size, whereas
the addition of carnitine to the perfusion solution diminished
the cardioprotective effect of methyl-GBB (fig. 1B).
Plasma concentration of methyl-GBB and heart tissue
concentrations of methyl-GBB, GBB and carnitine.
Methyl-GBB concentration in plasma reached 24  1.8 lM
at the end of the 28-day treatment was significantly lower
14 days post-treatment (14.8  1.3 lM), and at 28 days after
the last administration of the drug, the concentration of
methyl-GBB was 10.1  0.5 lM. The elimination of methyl-
GBB from plasma followed the one-compartment model (Fig-
ure S1A and B). The plasma half-life of methyl-GBB, as
determined by the single dose (5 mg/kg) administration, was
found to be 27 hr; the Cmax of methyl-GBB in the plasma was
reached in 4.4 hr. The elimination rate constants after acute
and chronic administration were 0.894 and 0.0304 days1,
respectively, indicating that plasma clearance is approximately
29 times faster than tissue clearance. The plasma half-life of
methyl-GBB after chronic administration largely reflected
elimination from all tissues and was determined to be
32.9 days (Figure S1B).
The average content of carnitine in the heart was
703  55 nmol/g tissue (622–732 nmol/g tissue) in the
Control group. Treatment with methyl-GBB for 28 days
decreased the heart tissue content of carnitine by an average
of 94% (table 1). Carnitine content in the heart tissues gradu-
ally recovered over time but was still decreased by 54%
28 days after the last administration of methyl-GBB. The con-
tent of methyl-GBB in the heart tissues after 28 days of treat-
ment was 217 nmol/g tissue. After the last administration, the
content of methyl-GBB started to decrease; however, even
after 28 days, 114 nmol/g tissue or 53% of the maximal con-
tent of methyl-GBB remained present in the heart tissues
(table 1); methyl-GBB elimination from the heart tissue was
linear (Figure S2). The content of GBB after 28 days of treat-
ment with methyl-GBB was increased two times (table 1) and
gradually decreased over the following 28 days.
The acute addition of 2 mM carnitine to the isolated heart
perfusion solution had no significant effect on carnitine levels
in methyl-GBB-treated hearts (117  16 nmol/g tissue in the


































































































Fig. 1. Per cent values of infarct size and corresponding per cent val-
ues of LCACs found in ischaemic tissues. For Panel A, infarct size
and LCAC values represent the mean  S.E.M. of seven hearts in
methyl-GBB-treated groups and are calculated as the percentage of the
average respective age-matched Control group values. For panel B,
infarct size and LCAC values represent the mean  S.E.M. of six
hearts in Control and methyl-GBB groups and seven hearts in methyl-
GBB+2 mM carnitine group and are calculated as the percentage of
the average respective Control group values. *p < 0.05 infarct size in
methyl-GBB group versus respective age-matched control (Student’s
t-test), #p < 0.05 LCAC level in methyl-GBB group versus respective
age-matched control (Student’s t-test), $p < 0.05 significantly different
from respective Control group (ANOVA followed by Tukey’s test).
Dashed line represents 30% of LCAC remaining (70% decrease in
LCAC content).
© 2017 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
108 JANIS KUKA ET AL.
methyl-GBB+carnitine group). Similarly, the acute addition of
2 mM carnitine had no significant effect on GBB levels
in methyl-GBB-treated hearts (58  8 nmol/g tissue in the
methyl-GBB group versus 70  6 nmol/g tissue in
the methyl-GBB+carnitine group).
Plasma and heart tissue concentrations of acylcarnitines.
The average concentration of SCACs (C2 and C4) in the
plasma was 25.1 lM (15–31 lM) in the Control group rats,
and treatment with methyl-GBB for 28 days decreased the
acylcarnitine plasma concentration by 75% (table 2). The con-
centration of SCACs gradually recovered over time but was
52% lower than that in the Control group even 28 days after
the end of the treatment. The average concentration of MCACs
(C6-C12) was 39 nM (29–44 nM) in the Control group and
was similarly decreased by 61% after treatment with methyl-
GBB. The concentration of MCACs was 46% lower than that
in the Control group 28 days after the end of the treatment
(table 2). The average concentration of LCACs (C14-C18:2) in
the plasma was 213 nM (173–232 nM) in the Control group
and was similarly decreased by 52% after treatment with
methyl-GBB. The concentration of LCACs was 34% lower at
28 days after the end of the treatment compared to the Control
group (table 2). The recovery of LCACs was statistically sig-
nificantly more pronounced than the recovery of MCACs in
the plasma of rats treated with methyl-GBB. The entire acylcar-
nitine profile in plasma is included in the Table S3.
The average content of SCACs in the heart was 712 nmol/g
tissue (638–811 nmol/g tissue) in the Control group, and treat-
ment with methyl-GBB for 28 days decreased the acylcar-
nitine heart tissue content by 92% (fig. 3A). Overall, the
recovery of acylcarnitine levels in the heart was similar to
the changes in plasma. No significant differences among the
recoveries of various chain length acylcarnitines in the heart
tissues could be observed in the hearts of methyl-GBB-treated
animals. The content of SCACs gradually recovered but was

































































Fig. 2. Pearson correlation of infarct size and LCAC (A) and carnitine
(B) contents in methyl-GBB-treated rat hearts. Each % value was cal-
culated as the percentage of the average respective age-matched Con-
trol group values. Square markers indicate 28-day treatment, rhomb
markers indicate 14 days post-treatment and triangle markers indicate
28 days post-treatment.
Table 1.
The effect of methyl-GBB administration on carnitine, methyl-GBB
and GBB concentrations in heart tissues after 28 days of treatment








Control 622  66 756  39 732  60
Methyl-GBB 36  4* 129  10* 337  75*
Methyl-GBB, nmol/g
Control nd nd nd
Methyl-GBB 217  9 157  10** 114  6**,***
GBB, nmol/g
Control 31.7  1.3 28.2  1.8 25.5  1.8
Methyl-GBB 61.5  2.7* 61.9  3.7* 49.9  3.7*
Each value represents the mean  S.E.M. of six rats in Control
groups and seven rats in methyl-GBB treatment groups.
*Significantly different from the respective age-matched Control group
(Student’s t-test, p < 0.05).
**Significantly different from the 28-day methyl-GBB treatment group
(Tukey’s test; p < 0.05).
***Significantly different from the 14-day post-treatment group
(Tukey’s test; p < 0.05). nd – not detectable.
Table 2.
The effect of methyl-GBB administration on short-chain (SCAC),
medium-chain (MCAC) and long-chain (LCAC) acylcarnitine levels in
the plasma after 28 days of treatment and at 14 and 28 days after the








Control 15  1.4 28  1.6 31  2.3
Methyl-GBB 3.8  0.3* 9.3  0.7* 15  0.8*
MCAC, nM
Control 29  1.5 43  3.8 44  5.3
Methyl-GBB 11.2  1.0* 21  1.5* 24  1.0*
LCAC, nM
Control 173  19 227  22 232  19
Methyl-GBB 83  5* 142  15* 154  13*
Each value calculated as the mean  S.E.M. of six rats in Control
groups and seven rats in methyl-GBB treatment group.
*Significantly different from the respective age-matched Control group
(Student`s t-test, p < 0.05).
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after the end of the treatment. The average content of MCACs
was 1193 pmol/g tissue (1055–1350 pmol/g tissue) in the
Control group and was decreased by 90% after treatment with
methyl-GBB. The content of MCACs also recovered gradually
(fig. 3B) and was 51% lower than that in the Control group
even at 28 days after the end of the treatment. The average
content of LCACs was 22.1 nmol/g tissue (17–25 nmol/g tis-
sue) in the Control group and was decreased by 87% after
treatment with methyl-GBB (fig. 3C). The content of LCACs
was 69% lower than that in the Control group 14 days post-
treatment (anti-infarction effect present) and 59% lower
28 days post-treatment when anti-infarction effect was not pre-
sent (fig. 1A). The entire acylcarnitine profile in heart tissues
is included in Table S4.
The acute addition of 2 mM carnitine to the isolated heart
perfusion solution had no significant effect on the levels of
short- and medium-chain acylcarnitines compared to the
methyl-GBB-treated hearts. The contents of short- and medium-
chain acylcarnitines in the methyl-GBB group (103  14 nmol/
g tissue for SCACs and 335  46 pmol/g tissue for MCACs)
and in the methyl-GBB+carnitine group (102  9 nmol/g tissue
for SCACs and 288  8 pmol/g tissue for MCACs) were signif-
icantly lower than those in the Control group (520  35 nmol/g
tissue for SCACs and 636  52 pmol/g tissue for MCACs in
the Control group). LCAC content was significantly decreased
in the methyl-GBB group (0.9  0.1 nmol/g tissues) compared
to the Control group (5.1  0.8 nmol/g tissues); however, when
2 mM carnitine were added to the perfusion solution, the LCAC
content in the methyl-GBB+carnitine group was significantly
higher (1.7  0.3 nmol/g tissues) than that in the methyl-GBB
group (fig. 1B). Content of LCAC in the methyl-GBB+carnitine
group remained significantly lower (by 67%) than that in the
Control group, but no anti-infarction effect could be observed
(fig. 1B).
Discussion
The present study demonstrates that methyl-GBB can effec-
tively compete with carnitine for OCTN2-mediated transport
and is effectively retained in the tissues over a prolonged per-
iod of time. The prolonged presence of methyl-GBB is concor-
dant with lowered carnitine levels and a significantly decreased
content of acylcarnitines, in particular, LCACs, which con-
tribute to the severity of ischaemia–reperfusion-induced mito-
chondrial and cardiomyocyte damage. In this study, based on
rat isolated heart infarction model, we further highlight the
detrimental contribution that long-chain acylcarnitines have in
the outcome of heart ischaemia–reperfusion-induced damage.
Previously, it has been shown that OCTN2 is highly speci-
fic towards carnitine and structurally related organic cations
and is a key transporter that ensures the uptake of the cardio-
protective compound, meldonium, in tissues [19]. The results
of the present study provide evidence that the tissue distribu-
tion of methyl-GBB follows a similar pattern. However,
methyl-GBB at a 20 times lower dose has better anti-infarction
effect in the isolated rat heart model compared to meldonium
[8]; this can at least partially be explained by the greater affin-
ity of methyl-GBB for OCTN2, which results in lower car-
nitine level and subsequent LCAC content compared to
meldonium-induced effects. Previously, we found that the co-
treatment of meldonium with carnitine prevents the decrease
in carnitine content, and no cardioprotective effect was
observed when the carnitine content was decreased by less
than approximately 60% [22]. Methyl-GBB decreases carnitine
levels significantly better than meldonium, and the contents of







































































































Fig. 3. The effect of methyl-GBB administration on short-chain (A),
medium-chain (B) and long-chain (C) acylcarnitine contents in heart
tissues after 28 days of treatment and at 14 and 28 days after the last
day of treatment. Each value was calculated as the mean  S.E.M. of
six hearts in Control groups and seven hearts in methyl-GBB treated
groups. *Significantly different from the respective age-matched Con-
trol group (Student’s t-test; p < 0.05).
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tissues were decreased even at 28 days post-treatment with
methyl-GBB; however, no anti-infarction effect was observed
(fig. 1A). When an infarction study was performed at 14 days
post-treatment, the levels of carnitine were decreased by 83%
and levels of LCACs by 69%. A similar decrease in carnitine
content was observed immediately after 14 days of methyl-
GBB treatment [8]. The decrease in infarct size that was
observed at 14 days post-treatment is comparable to the mel-
donium (14 days, 100 mg/kg)-induced cardioprotective effect
[22] and the methyl-GBB anti-infarction effect after only
7 days of treatment [8]. Altogether, these findings indicate that
carnitine content in the heart should be decreased by 60–70%
so that LCAC content could be decreased by 70% to signifi-
cantly reduce the infarct size by 20%. Apparently, if the
LCAC content in rat heart tissues is decreased by at least 84–
87% as observed in the present study and previously by our
group [8], only then can one expect a robust cardioprotective
effect like a reduction in infarct size of greater than 50%.
Previously, it has been noted that the supplementation of
carnitine to the perfusion solution worsens global ischaemia
outcome by impairing glucose metabolism [23]. This can be
explained by the ability of LCACs at physiological levels to
decrease glucose metabolism both in an isolated heart setup
and in vivo [24], and acylcarnitine levels were increased after
supplementation with carnitine [28]. In this study, when
2 mM carnitine were added to the perfusion buffer solution,
no significant increase in carnitine tissue content was observed
because all supplemented carnitine was used for LCAC syn-
thesis, resulting in an almost two times increase in LCAC
levels (67% decrease) compared to those observed in the
methyl-GBB group (83% decrease), and the anti-infarction
effect of methyl-GBB was not present (fig. 1B). After 28 days
of treatment, the anti-infarction effect of methyl-GBB was cor-
related with a decrease in the contents of all chain length acyl-
carnitines and free carnitine. However, the acute addition of
2 mM carnitine significantly increased only LCAC content.
Moreover, it has been shown that, unlike LCAC [24], SCAC
and MCAC cannot significantly impair mitochondrial energy
metabolism [29]. Altogether, these findings indicate that under
acute ischaemic conditions, mitochondrial LCAC content is
far more important than the contents of carnitine or short- and
medium-chain acylcarnitines.
Incomplete fatty acid oxidation may lead to accumulation of
LCAC, long-chain acyl-coenzyme A esters, diacylglycerol, tri-
acylglycerol and ceramide that can impair energy metabolism
[2,3,30]. Long-chain acyl-coenzyme A esters are potentially
highly toxic [31,32], however, during ischaemia LCAC, but
not long-chain acyl-coenzyme A esters, accumulate at concen-
trations that are harmful to mitochondria [11]. Acylcarnitine
accumulation is one of the multiple factors that contribute to
the ischaemia–reperfusion damage by affecting cell insulin sig-
nalling [5,6], modulation of cell membrane ion channels,
changes in membrane permeability and activation of cell stress
pathways [7]. Current and previous findings have shown that
compounds like meldonium and methyl-GBB that significantly
decrease LCAC tissue content also decrease infarct size by 30–
50%. This allows to speculate that detrimental effects of LCAC
accumulation could account for an important part of necrotic
damage in ischaemic tissues. The only currently known mecha-
nism of anti-infarction effect of meldonium and methyl-GBB is
related to the decrease in carnitine and LCAC contents. Results
from experiments with meldonium [33] and methyl-GBB (un-
published data) indicate that decrease in carnitine tissue content
has no significant effect on contents of free fatty acids and
long-chain acyl-coenzyme A in the heart. Decreased acylcar-
nitine formation after treatment with methyl-GBB leads to low-
ered fatty acid oxidation in the heart [8]. As fatty acids and
glucose compete for contribution in energy production, methyl-
GBB treatment increases basal and insulin-stimulated glucose
metabolism [8]. Nevertheless, competition of glucose and fatty
acid metabolism pathways is effectively mediated by LCACs
at both cellular and mitochondrial levels [5,6,24] and decrease
in LCAC content improves insulin signalling and facilitates
glucose metabolism, that is more energy efficient during
hypoxic conditions [34]. Thus, decrease in carnitine and LCAC
levels leads to changes in energy metabolism pathways and
results in less severe ischaemia-induced damage in the heart.
Conclusions
The anti-infarction effect of methyl-GBB continues for at least
2 weeks post-treatment. LCAC tissue content decreased by
70% leads to moderate infarct size decrease, but maximum
anti-infarction effect can be observed when LCAC content is
decreased by 87%. The decrease in LCAC levels defines the
duration of the post-treatment cardioprotective effect of the
OCTN2 inhibitor, methyl-GBB.
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